Palo Alto, CA, USA – November, 2024 – Genascence Corporation (“Genascence”), a clinical-stage biotechnology company pioneering gene therapy for the treatment of prevalent musculoskeletal diseases, has announced the appointment of Dr. Jeymi Tambiah, MBChB, FRCS, MS, FAPCR, MFPM(Dis), as its new Chief Medical Officer. Dr. Tambiah brings over 15 years of biopharmaceutical industry experience, having led strategies in medical affairs, clinical development, and drug development programs, along with significant expertise in translational medicine, commercialization, and health outcomes research.
Thomas Chalberg, Founder and CEO of Genascence, shared his enthusiasm for Dr. Tambiah’s appointment: “Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in the areas of osteoarthritis, immunology, oncology, and neuroscience, and I am excited to welcome him to Genascence as our Chief Medical Officer. His experience includes all phases of drug development from bench through Phase 1-4 clinical studies and building elite high-performance medical affairs teams. Jeymi’s development and research expertise, particularly within the osteoarthritis research community, will be invaluable as we execute on our strategy to bring gene therapy to people suffering from prevalent musculoskeletal diseases.”
Dr. Tambiah expressed his enthusiasm: “Genascence is a company that is transforming how we treat debilitating musculoskeletal diseases like osteoarthritis by pioneering the development of gene therapy. I am thrilled to join this outstanding team under Tom’s leadership and apply my knowledge and experience to advance our clinical program so that we can bring potentially curative therapies to patients in desperate need of better treatments.”
Prior to joining Genascence, Dr. Tambiah served as Senior Vice President of Clinical Development and External Innovation at Biosplice Therapeutics, a biotech start-up focused on mRNA splicing modulation for oncology, arthritis, and neurodegenerative diseases. He has also held senior roles at UCB Pharma, where he was instrumental in launching the TNF-inhibitor certolizumab pegol in the EU, UK, and US for multiple immunology indications. Dr. Tambiah trained and practiced in cardiothoracic surgery at Guys’ and St. Thomas’ Hospitals in London.
Dr. Tambiah holds a medical degree from the University of Manchester, a doctorate in vascular biology from Imperial College London (where he was a Wellcome Research Fellow), and a BSc (Hons) in medical science from the University of St. Andrews. He is a fellow of the Royal College of Surgeons of England and Edinburgh, a Fellow of the Academy of Physicians in Clinical Research, and an active member of the osteoarthritis research community.
About Genascence Corporation:
Genascence is a clinical-stage biotechnology company developing gene therapies to address musculoskeletal diseases, aiming to bring transformative treatments to millions of patients. Founded in 2017 with technology licensed from the Mayo Clinic, University of Florida, and NYU Langone Health, Genascence is headquartered in Palo Alto, California. The company’s leadership team possesses deep expertise in designing, developing, and manufacturing successful gene therapies and biological medicines.
Read Also : Cultivating Safe Spaces: The Strategic Role of L&D in Workplace Well-being
